Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells
By Satoko Matsumura, Baomei Wang, N. Kawashima, S. Braunstein, M. Badura, T. Cameron, J. Babb, R. Schneider, S. Formenti, Michael Loran Dustin and 1 more. Journal of Immunology, 2008
674 citations recorded by the source corpus.
Recruitment of effector T cells to inflamed peripheral tissues is regulated by chemokines and their receptors, but the factors regulating recruitment to tumors remain largely undefined. Ionizing radiation (IR) therapy is a common treatment modality for breast and other cancers. Used as a cytocidal agent for proliferating cancer cells, IR in combination with immunotherapy has been shown to promote immune-mediated tumor destruction in preclinical studies. In this study we demonstrate that IR markedly enhanced the secretion by mouse and human breast cancer cells of CXCL16, a chemokine that binds to CXCR6 on Th1 and activated CD8 effector T cells, and plays an important role in their recruitment to sites of inflammation. Using a poorly immunogenic mouse model of breast cancer, we found that irradiation increased the migration of CD8+CXCR6+ activated T cells to tumors in vitro and in vivo. CXCR6-deficient mice showed reduced infiltration of tumors by activated CD8 T cells and impaired tumor regression following treatment with local IR to the tumor and Abs blocking the negative regulator of T cell activation, CTLA-4. These results provide the first evidence that IR can induce the secretion by cancer cells of proinflammatory chemotactic factors that recruit antitumor effector T cells. The ability of IR to convert tumors into “inflamed” peripheral tissues could be exploited to overcome obstacles at the effector phase of the antitumor immune response and improve the therapeutic efficacy of immunotherapy.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/1d8c0db599aec92f28ce5a855ef1138d7f1e1339
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors (2014, neutral): “On the other hand, expression of CXCL16 in tumors has been associated with improved outcomes and increased antitumor immune responses in cancers of the colon, breast, and kidney (Hojo et al., 2007; Matsumura et al., 2008; Gutwein et al., 2009).”
- Combining radiotherapy and cancer immunotherapy: a paradigm shift. (2013, background): “CXCL16 improved recruitment to the tumor of CXCR6+ effector CD8 T cells (31).”
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer (2013, background): “The synergy between radiotherapy and anti-CTLA-4 antibody was at least in part due to improved recruitment of these effector T cells to the tumor and their enhanced interaction with tumor cells via NKG2D receptor engagement (16, 27).”